MR1-Restricted T Cells Are Unprecedented Cancer Fighters.
-
Vacchini A
Experimental Immunology, Department of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
-
Chancellor A
Experimental Immunology, Department of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
-
Spagnuolo J
Experimental Immunology, Department of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
-
Mori L
Experimental Immunology, Department of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
-
De Libero G
Experimental Immunology, Department of Biomedicine, University of Basel and University Hospital Basel, Basel, Switzerland.
Show more…
Published in:
- Frontiers in immunology. - 2020
English
Non-polymorphic MHC class I-related molecule MR1 presents antigenic bacterial metabolites to mucosal-associated invariant T (MAIT) cells and self-antigens to MR1-restricted T (MR1T) cells. Both MR1-restricted T cell populations are readily identified in healthy individuals, with MAIT cells accounting for 1-10% of circulating T cells, while MR1T cells have frequencies comparable to peptide-specific T cells (<0.1%). Self-reactive MR1T cells display a heterogeneous phenotype, and are capable of releasing both TH1 and TH2 cytokines, supporting not only activation of inflammation but also contributing to its regulation. Importantly, MR1T cells recognize and kill a diverse range of MR1-expressing tumor cells. On the other hand, evidence suggests MAIT cells augment cancer growth and metastases. This review addresses the potential role of MR1-restricted T cells in controlling tumor cells, facilitating their elimination and regulating cancer immunity. We also discuss therapeutic opportunities surrounding MR1-restricted T cells in cancer.
-
Language
-
-
Open access status
-
gold
-
Identifiers
-
-
Persistent URL
-
https://folia.unifr.ch/global/documents/160439
Statistics
Document views: 23
File downloads: